HRP20030943B1 - Optičko razdvajanje (1-benzil-4-metilpiperidin-3-il)-metilamina i njegova upotreba u dobivanju pirolo 2,3-pirimidinskih derivata kao inhibitora protein kinaze - Google Patents

Optičko razdvajanje (1-benzil-4-metilpiperidin-3-il)-metilamina i njegova upotreba u dobivanju pirolo 2,3-pirimidinskih derivata kao inhibitora protein kinaze

Info

Publication number: HRP20030943B1
Authority: HR; Croatia
Prior art keywords: alkyl; amino; acylamino; alkylamino; group
Prior art date: 2001-05-31

Application number

HR20030943A

Other languages

English (en)

Croatian (hr)

Inventor

Ernest Wilcox Glenn

Koecher Christian

Vries Ton

Edward Flanagan Mark

John Munchhof Michael

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-31

Filing date

2002-05-29

Publication date

2011-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030943(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-05-29 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-08-31 Publication of HRP20030943A2 publication Critical patent/HRP20030943A2/xx

2011-11-30 Publication of HRP20030943B1 publication Critical patent/HRP20030943B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HR20030943A 2001-05-31 2002-05-29 Optičko razdvajanje (1-benzil-4-metilpiperidin-3-il)-metilamina i njegova upotreba u dobivanju pirolo 2,3-pirimidinskih derivata kao inhibitora protein kinaze HRP20030943B1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29477501P	2001-05-31	2001-05-31
US34104801P	2001-12-06	2001-12-06
PCT/IB2002/001905 WO2002096909A1 (en)	2001-05-31	2002-05-29	Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors

Publications (2)

Publication Number	Publication Date
HRP20030943A2 HRP20030943A2 (en)	2005-08-31
HRP20030943B1 true HRP20030943B1 (hr)	2011-11-30

Family

ID=26968730

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20030943A HRP20030943B1 (hr)	2001-05-31	2002-05-29	Optičko razdvajanje (1-benzil-4-metilpiperidin-3-il)-metilamina i njegova upotreba u dobivanju pirolo 2,3-pirimidinskih derivata kao inhibitora protein kinaze

Country Status (52)

Country	Link
US (2)	US7301023B2 (is)
EP (3)	EP1609781B1 (is)
JP (1)	JP4381137B2 (is)
KR (5)	KR100869409B1 (is)
CN (1)	CN1729192A (is)
AP (1)	AP1859A (is)
AR (2)	AR037321A1 (is)
AT (1)	ATE519741T1 (is)
AU (2)	AU2002304401C1 (is)
BE (1)	BE2017C032I2 (is)
BG (1)	BG66489B1 (is)
BR (1)	BR0209246A (is)
CA (1)	CA2448281C (is)
CL (1)	CL2008000762A1 (is)
CR (1)	CR10177A (is)
CU (1)	CU23337B7 (is)
CY (2)	CY1113322T1 (is)
CZ (1)	CZ304366B6 (is)
DK (1)	DK1666481T3 (is)
EA (2)	EA007251B1 (is)
EC (1)	ECSP034865A (is)
EE (1)	EE05332B1 (is)
ES (2)	ES2369226T3 (is)
FR (1)	FR17C1031I2 (is)
GE (1)	GEP20063784B (is)
GT (2)	GT200200100AA (is)
HR (1)	HRP20030943B1 (is)
HU (2)	HU230876B1 (is)
IL (1)	IL158588A0 (is)
IS (1)	IS3023B (is)
LT (1)	LTC1666481I2 (is)
LU (1)	LUC00031I2 (is)
MA (1)	MA27029A1 (is)
MX (1)	MXPA03011062A (is)
MY (1)	MY129649A (is)
NL (1)	NL300887I2 (is)
NO (3)	NO328578B1 (is)
NZ (2)	NZ530380A (is)
OA (1)	OA12612A (is)
PA (1)	PA8546301A1 (is)
PE (1)	PE20030561A1 (is)
PL (2)	PL228155B1 (is)
PT (1)	PT1666481E (is)
RS (1)	RS52144B (is)
SI (1)	SI1666481T1 (is)
SK (2)	SK288192B6 (is)
TN (1)	TNSN03128A1 (is)
TW (2)	TWI310384B (is)
UA (1)	UA80093C2 (is)
UY (1)	UY27317A1 (is)
WO (1)	WO2002096909A1 (is)
ZA (1)	ZA200307982B (is)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
DE60037345T2 (de)	1999-12-10	2008-11-13	Pfizer Products Inc., Groton	Pyrrolo(2,3-d)pyrimidin-Verbindungen
AU784297C (en) *	2000-06-26	2007-01-11	Pfizer Products Inc.	Pyrrolo(2,3-d)pyrimidine compounds as immunosuppressive agents
GT200200234A (es)	2001-12-06	2003-06-27		Compuestos cristalinos novedosos
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
JP2006514989A (ja)	2002-07-29	2006-05-18	ライジェルファーマシューティカルズ	２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
CN1678314A (zh) *	2002-08-27	2005-10-05	默克专利有限公司	作为raf－激酶抑制剂的甘氨酸酰胺衍生物
AU2003276591A1 (en)	2002-11-26	2004-06-18	Pfizer Products Inc.	Method of treatment of transplant rejection
AU2004265288A1 (en)	2003-07-30	2005-02-24	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
RU2415678C2 (ru) *	2004-05-03	2011-04-10	Новартис Аг	Комбинации, включающие агонист рецептора s1p и ингибитор киназы jak3
US7358250B2 (en)	2004-06-29	2008-04-15	Amgen Inc.	Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity
EP1797054A2 (en)	2004-08-02	2007-06-20	OSI Pharmaceuticals, Inc.	Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
BRPI0517887A (pt) *	2004-11-24	2008-10-21	Novartis Ag	combinações de inibidores de jaks
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
NZ563454A (en)	2005-06-08	2011-03-31	Rigel Pharmaceuticals Inc	2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2007007919A2 (en)	2005-07-14	2007-01-18	Astellas Pharma Inc.	Heterocyclic janus kinase 3 inhibitors
EP2251341A1 (en)	2005-07-14	2010-11-17	Astellas Pharma Inc.	Heterocyclic Janus kinase 3 inhibitors
NZ565363A (en)	2005-07-29	2010-03-26	Pfizer Prod Inc	Pyrrolo[2,3-D]pyrimidine derivatives; their intermediates and synthesis
EP2270014A1 (en)	2005-09-22	2011-01-05	Incyte Corporation	Azepine inhibitors of janus kinases
HUE025173T2 (hu)	2005-12-13	2016-01-28	Incyte Corp	Heteroaril-szubsztituált pirrollo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JP2009528295A (ja)	2006-02-24	2009-08-06	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
GB0605691D0 (en) *	2006-03-21	2006-05-03	Novartis Ag	Organic Compounds
EP2121692B1 (en)	2006-12-22	2013-04-10	Incyte Corporation	Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP3070090B1 (en)	2007-06-13	2018-12-12	Incyte Holdings Corporation	Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
WO2009007839A1 (en) *	2007-07-11	2009-01-15	Pfizer Inc.	Pharmaceutical compositions and methods of treating dry eye disorders
CA2715658C (en)	2008-02-15	2016-07-19	Rigel Pharmaceuticals, Inc.	Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
HUE029767T2 (en)	2008-03-11	2017-04-28	Incyte Holdings Corp	JAK inhibitor azetidine and cyclobutane derivatives
PT2323993E (pt)	2008-04-16	2015-10-12	Portola Pharm Inc	2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
BRPI0910668A2 (pt)	2008-04-22	2019-09-24	Portola Pharmaceutiacals Inc	inibidores de proteína quinases
WO2010014930A2 (en) *	2008-08-01	2010-02-04	Biocryst Pharmaceuticals, Inc.	Therapeutic agents
PT2384326E (pt)	2008-08-20	2014-06-09	Zoetis Llc	Compostos de pirrolo[2,3-d]pirimidina
JP2012517448A (ja) *	2009-02-11	2012-08-02	リアクションバイオロジーコープ．	選択的キナーゼ阻害剤
CN104817561B (zh)	2009-04-20	2017-06-13	奥斯拜客斯制药有限公司	Janus激酶3的哌啶抑制剂
LT2432472T (lt)	2009-05-22	2020-02-10	Incyte Holdings Corporation	3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
TW201100429A (en)	2009-05-22	2011-01-01	Incyte Corp	N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AR078012A1 (es)	2009-09-01	2011-10-05	Incyte Corp	Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
EP2475667A1 (en) *	2009-09-10	2012-07-18	F. Hoffmann-La Roche AG	Inhibitors of jak
US8486902B2 (en)	2009-10-09	2013-07-16	Incyte Corporation	Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CN102574860A (zh)	2009-10-15	2012-07-11	辉瑞大药厂	吡咯并[2,3-d]嘧啶化合物
ES2461967T3 (es)	2009-12-18	2014-05-21	Pfizer Inc.	Compuestos de pirrolo[2,3-d]pirimidina
EP2523957A1 (en) *	2010-01-12	2012-11-21	F. Hoffmann-La Roche AG	Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2011097087A1 (en)	2010-02-05	2011-08-11	Pfizer Inc.	Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
CA2792508C (en)	2010-03-10	2018-01-16	Incyte Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
TWI499421B (zh)	2010-05-21	2015-09-11	Incyte Corp	Ｊａｋ抑制劑的局部製劑
EP2975027A1 (en)	2010-11-01	2016-01-20	Portola Pharmaceuticals, Inc.	Nicotinamides as jak kinase modulators
JP5917544B2 (ja)	2010-11-19	2016-05-18	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
AU2011329734B2 (en)	2010-11-19	2015-05-28	Incyte Holdings Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
EP2481411A1 (en)	2011-01-27	2012-08-01	Ratiopharm GmbH	Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2481397A1 (en)	2011-01-27	2012-08-01	Ratiopharm GmbH	Pharmaceutical compositions comprising tasocitinib
KR102024948B1 (ko)	2011-02-18	2019-11-04	노파르티스 파르마 아게	mTOR/JAK 저해제 병용 요법
EP2691395B1 (en)	2011-03-28	2017-08-30	ratiopharm GmbH	Processes for preparing tofacitinib salts
US9050342B2 (en)	2011-03-29	2015-06-09	Pfizer Inc.	Beneficial effects of combination therapy on cholesterol
AU2012241018B2 (en) *	2011-04-08	2015-11-12	Pfizer Inc.	Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
EP2524688B1 (en)	2011-05-11	2013-05-01	ratiopharm GmbH	Composition for modified release comprising ranolazine
ES2560611T3 (es)	2011-06-20	2016-02-22	Incyte Holdings Corporation	Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
CA2844507A1 (en)	2011-08-10	2013-02-14	Novartis Pharma Ag	Jak pi3k/mtor combination therapy
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
US9359308B2 (en)	2011-11-23	2016-06-07	Portola Pharmaceuticals, Inc.	Pyrazine kinase inhibitors
US10821111B2 (en)	2011-11-30	2020-11-03	Emory University	Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
ES3018133T3 (en) *	2011-11-30	2025-05-14	Univ Emory	Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013090490A1 (en)	2011-12-15	2013-06-20	Ratiopharm Gmbh	Tofacitinib salts
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
WO2014016338A1 (en)	2012-07-25	2014-01-30	Lek Pharmaceuticals D.D.	New synthetic route for the preparation of 3-amino-piperidine compounds
EP2903970A4 (en)	2012-10-08	2016-11-30	Portola Pharm Inc	SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
SG10202111768XA (en)	2012-11-15	2021-11-29	Incyte Holdings Corp	Sustained-release dosage forms of ruxolitinib
CN104955803B (zh) *	2012-11-30	2017-11-28	斯洛文尼亚莱柯制药股份有限公司	通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
EP2935216B1 (en)	2012-12-17	2018-06-27	Sun Pharmaceutical Industries Limited	Process for the preparation of tofacitinib and intermediates thereof
WO2014102826A1 (en)	2012-12-28	2014-07-03	Glenmark Pharmaceuticals Limited;	The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
KR101787858B1 (ko)	2013-02-22	2017-10-18	화이자 인코포레이티드	야누스-관련된 키나아제의 억제제로서의 피롤로 [2,3-d]피리미딘 유도체
PE20200298A1 (es)	2013-03-06	2020-02-06	Incyte Holdings Corp	Procesos e intermedios para hacer un inhibidor de jak
JP6041823B2 (ja)	2013-03-16	2016-12-14	ファイザー・インク	トファシチニブの経口持続放出剤形
US20140343034A1 (en)	2013-04-25	2014-11-20	Japan Tobacco Inc.	Skin barrier function improving agent
WO2014174073A1 (en)	2013-04-26	2014-10-30	Sandoz Ag	Sustained release formulations of tofacitinib
CN114010611B (zh)	2013-08-07	2023-11-28	因赛特控股公司	Jak1抑制剂的持续释放剂型
CN104513248B (zh) *	2013-09-30	2019-05-24	重庆医药工业研究院有限责任公司	一种托法替尼中间体的纯化方法
PE20161246A1 (es)	2013-12-05	2016-11-25	Pfizer	Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
PT3539965T (pt)	2013-12-09	2021-04-07	Unichem Lab Ltd	Processo melhorado para a preparação de (3r,4r)-(1-benzil-4-metilpiperidin-3-il)-metilamina
US9260438B2 (en)	2014-02-06	2016-02-16	Apotex Inc.	Solid forms of tofacitinib salts
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
ES2750655T3 (es)	2014-08-12	2020-03-26	Pfizer	Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
WO2016116025A1 (zh) *	2015-01-20	2016-07-28	南京明德新药研发股份有限公司	Jak抑制剂
BR112017001516B1 (pt) *	2015-02-17	2023-10-31	Amorepacific Corporation	Método de ressolubilização quiral, estereoisômero, método para preparar um composto, composto, composição, e kit de ressolubilização quiral
CN104761556B (zh) *	2015-03-21	2017-06-23	河北国龙制药有限公司	托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
EP3078665A1 (en)	2015-04-10	2016-10-12	OLON S.p.A.	Efficient method for the preparation of tofacitinib citrate
HUE044240T2 (hu)	2015-04-29	2019-10-28	Wuxi Fortune Pharmaceutical Co Ltd	Janus kináz (JAK) inhibitorok
EP3288943B1 (en)	2015-05-01	2022-09-28	Pfizer Inc.	Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase
KR102081272B1 (ko)	2015-05-29	2020-02-25	우시 포춘 파마슈티컬 컴퍼니 리미티드	Janus 키나아제 억제제
KR101964546B1 (ko) *	2015-07-27	2019-04-01	유니켐 레버러토리스 리미티드	토파시티닙 경구 붕해 정제
KR101771219B1 (ko) *	2015-08-21	2017-09-05	양지화학 주식회사	야누스 키나제 1 선택적 억제제 및 그 의약 용도
WO2017091681A1 (en)	2015-11-24	2017-06-01	Aclaris Therapeutics, Inc.	Selective kinase inhibitors
CN105348287A (zh) *	2015-11-30	2016-02-24	宁波立华制药有限公司	一种枸橼酸托法替布的新型合成工艺
KR102565407B1 (ko) *	2016-01-04	2023-08-10	(주)아모레퍼시픽	극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
US20190083609A1 (en)	2016-01-18	2019-03-21	Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh)	Tofacitinib as vaccination immune modulator
BR112018074621B1 (pt)	2016-06-30	2021-06-08	Daewoong Pharmaceutical Co., Ltd	compostos derivados de pirazolopirimidina como inibidores de quinase, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
CN106831538B (zh) *	2017-01-22	2019-06-25	苏州楚凯药业有限公司	托法替尼中间体的制备方法
KR102398659B1 (ko)	2017-03-17	2022-05-16	주식회사 대웅제약	카이네이즈 저해제로서의 피롤로트리아진 유도체
CN107602569A (zh) *	2017-10-23	2018-01-19	上海博悦生物科技有限公司	一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
KR102078805B1 (ko)	2017-11-30	2020-02-19	보령제약 주식회사	토파시티닙을 포함하는 약제학적 조성물
TW201924683A (zh)	2017-12-08	2019-07-01	美商英塞特公司	用於治療骨髓增生性贅瘤的低劑量組合療法
KR102577241B1 (ko)	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
PE20201146A1 (es)	2017-12-28	2020-10-26	Dae Woong Pharma	Derivado de oxi-fluoropiperidina como inhibidor de quinasa
RS63312B1 (sr)	2018-01-30	2022-07-29	Incyte Corp	Procesi za pripremu (1-(3-fluoro-2-(trifluorometil)izonikotinil)piperidin-4-on)
CN111670036B (zh) *	2018-01-31	2024-08-09	安成生物科技股份有限公司	包含托法替尼的局部调配物
US12161748B2 (en)	2018-01-31	2024-12-10	Twi Biotechnology, Inc.	Topical formulations comprising tofacitinib
MX2020010322A (es)	2018-03-30	2022-11-30	Incyte Corp	Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
KR102131107B1 (ko) *	2019-01-15	2020-07-07	주식회사 다산제약	3-아미노-피페리딘 화합물의 신규한 제조 방법
NL2022471B1 (en)	2019-01-29	2020-08-18	Vationpharma B V	Solid state forms of oclacitinib
US12364696B2 (en)	2019-02-27	2025-07-22	Jak Slave Pty Ltd	Treatment of autoimmune disease
CA3132109A1 (en)	2019-03-13	2020-09-17	Intas Pharmaceuticals Ltd.	Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
WO2020198583A1 (en)	2019-03-27	2020-10-01	Insilico Medicine Ip Limited	Bicyclic jak inhibitors and uses thereof
KR102890724B1 (ko) *	2019-04-05	2025-11-25	주식회사유한양행	(3r,4r)-1-벤질-n,4-디메틸피페리딘-3-아민 또는 이의 염의 제조방법 및 이를 이용한 토파시티닙의 제조방법
CA3161153A1 (en)	2019-11-14	2021-05-20	Pfizer Inc.	1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
CN114728963B (zh) *	2019-11-25	2023-10-31	株式会社大熊制药	新型三唑吡啶衍生物和包括其的药物组合物
US20230149407A1 (en)	2020-04-04	2023-05-18	Pfizer Inc.	Methods of Treating Coronavirus Disease 2019
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
EP4308568A1 (en) *	2021-03-15	2024-01-24	Chiesi Farmaceutici S.p.A.	Heterocyclic derivatives as janus kinase inhibitors
CN113549075B (zh) *	2021-06-23	2025-09-23	合肥华方医药科技有限公司	一种枸橼酸托法替布非对映异构体杂质的合成方法
EP4180042A1 (en)	2021-11-15	2023-05-17	Sanovel Ilac Sanayi Ve Ticaret A.S.	A film coated tablet comprising micronized tofacitinib

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4814477A (en) *	1984-10-24	1989-03-21	Oce-Nederland B.V.	Dioxaphosphorinanes, their preparation and use for resolving optically active compounds
JPH07330732A (ja) *	1994-06-10	1995-12-19	Kyorin Pharmaceut Co Ltd	光学活性な３−アミノ−１−ベンジルピペリジン誘導体
WO1999065908A1 (en) *	1998-06-19	1999-12-23	Pfizer Products Inc.	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO1999065909A1 (en) *	1998-06-19	1999-12-23	Pfizer Products Inc.	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2001042246A2 (en) *	1999-12-10	2001-06-14	Pfizer Products Inc.	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2002000661A1 (en) *	2000-06-26	2002-01-03	Pfizer Products Inc.	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6136595A (en) *	1993-07-29	2000-10-24	St. Jude Children's Research Hospital	Jak kinases and regulations of cytokine signal transduction
US5389509A (en) *	1993-10-04	1995-02-14	Eastman Kodak Company	Ultrathin high chloride tabular grain emulsions
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ES2109796T3 (es)	1994-05-03	1998-01-16	Ciba Geigy Ag	Derivados de pirrolopirimidilo con efecto antiproliferante.
US6136596A (en) *	1995-05-19	2000-10-24	University Of Massachusetts	Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
WO1996040142A1 (en)	1995-06-07	1996-12-19	Pfizer Inc.	Heterocyclic ring-fused pyrimidine derivatives
MX9800136A (es)	1995-07-05	1998-03-29	Du Pont	Pirimidinonas fungicidas.
CA2224435C (en)	1995-07-06	2008-08-05	Novartis Ag	Pyrrolopyrimidines and processes for the preparation thereof
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
BR9607089A (pt)	1995-11-14	1997-11-11	Pharmacia & Upjohn Spa	Compostos de pirimidina condensada biciclica composição farmacéutica utilização e produtos que contém os mesmos e processo para a preparação desses compostos
ATE217873T1 (de)	1996-01-23	2002-06-15	Novartis Erfind Verwalt Gmbh	Pyrrolopyrimidinen und verfahren zu deren herstellung
CH690773A5 (de)	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en)	1996-02-29	1996-05-01	Pharmacia Spa	4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en)	1996-03-06	1997-09-22	Novartis Ag	7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en)	1996-06-25	1998-01-14	Novartis Ag	Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
EA199900021A1 (ru)	1996-07-13	1999-08-26	Глаксо, Груп Лимитед	Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
DE69738468T2 (de) *	1996-08-23	2009-01-08	Novartis Ag	Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
IL129825A0 (en)	1996-11-27	2000-02-29	Pfizer	Fused bicyclic pyrimidine derivatives
ES2301194T3 (es)	1997-02-05	2008-06-16	Warner-Lambert Company Llc	Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
EP0972197A1 (en) *	1997-03-24	2000-01-19	PHARMACIA & UPJOHN COMPANY	Method for identifying inhibitors of jak2/cytokine receptor binding
US6310063B1 (en)	1998-04-02	2001-10-30	Neurogen Corporation	Aminoalkyl substituted pyrrolo [3,2-E]pyridine and pyrollo [2,3-b]pyrimidine derivatives: modulators of CRF1 receptors
IL139641A0 (en)	1998-05-28	2002-02-10	Parker Hughes Inst	Quinazolines for treating brain tumor
JP2004504259A (ja)	1998-06-30	2004-02-12	パーカー　ヒューズ　インスティテュート	Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法
IL141434A0 (en)	1998-08-21	2002-03-10	Parker Hughes Inst	Quinazoline derivatives
US6080747A (en) *	1999-03-05	2000-06-27	Hughes Institute	JAK-3 inhibitors for treating allergic disorders
GT200200234A (es) *	2001-12-06	2003-06-27		Compuestos cristalinos novedosos
US7358250B2 (en) *	2004-06-29	2008-04-15	Amgen Inc.	Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity

2002
- 2002-05-23 US US10/154,699 patent/US7301023B2/en not_active Expired - Lifetime
- 2002-05-29 HU HUP0400152A patent/HU230876B1/hu active Protection Beyond IP Right Term
- 2002-05-29 CA CA002448281A patent/CA2448281C/en not_active Expired - Lifetime
- 2002-05-29 EA EA200301193A patent/EA007251B1/ru active Protection Beyond IP Right Term
- 2002-05-29 GE GE5361A patent/GEP20063784B/en unknown
- 2002-05-29 OA OA1200300308A patent/OA12612A/en unknown
- 2002-05-29 PT PT50154541T patent/PT1666481E/pt unknown
- 2002-05-29 KR KR1020067001821A patent/KR100869409B1/ko not_active Expired - Lifetime
- 2002-05-29 PL PL409305A patent/PL228155B1/pl unknown
- 2002-05-29 MX MXPA03011062A patent/MXPA03011062A/es active IP Right Grant
- 2002-05-29 SI SI200231004T patent/SI1666481T1/sl unknown
- 2002-05-29 KR KR1020077025832A patent/KR100868814B1/ko not_active Expired - Lifetime
- 2002-05-29 EP EP05015461A patent/EP1609781B1/en not_active Expired - Lifetime
- 2002-05-29 BR BR0209246-8A patent/BR0209246A/pt not_active Application Discontinuation
- 2002-05-29 JP JP2003500088A patent/JP4381137B2/ja not_active Expired - Lifetime
- 2002-05-29 TW TW091111480A patent/TWI310384B/zh active
- 2002-05-29 EP EP05015454.1A patent/EP1666481B9/en not_active Expired - Lifetime
- 2002-05-29 EE EEP200300594A patent/EE05332B1/xx active Protection Beyond IP Right Term
- 2002-05-29 KR KR1020087018519A patent/KR100926875B1/ko not_active Expired - Lifetime
- 2002-05-29 KR KR10-2003-7015681A patent/KR20040003037A/ko not_active Ceased
- 2002-05-29 DK DK05015454.1T patent/DK1666481T3/da active
- 2002-05-29 ES ES05015461T patent/ES2369226T3/es not_active Expired - Lifetime
- 2002-05-29 AT AT05015461T patent/ATE519741T1/de not_active IP Right Cessation
- 2002-05-29 ES ES05015454T patent/ES2393385T3/es not_active Expired - Lifetime
- 2002-05-29 UA UA20031110841A patent/UA80093C2/uk unknown
- 2002-05-29 TW TW092133699A patent/TWI316061B/zh not_active IP Right Cessation
- 2002-05-29 RS YU92303A patent/RS52144B/sr unknown
- 2002-05-29 AU AU2002304401A patent/AU2002304401C1/en not_active Expired
- 2002-05-29 TN TNPCT/IB2002/001905A patent/TNSN03128A1/fr unknown
- 2002-05-29 NZ NZ530380A patent/NZ530380A/en not_active IP Right Cessation
- 2002-05-29 PE PE2002000452A patent/PE20030561A1/es not_active Application Discontinuation
- 2002-05-29 IL IL15858802A patent/IL158588A0/xx active IP Right Grant
- 2002-05-29 KR KR1020067025590A patent/KR20060133117A/ko not_active Ceased
- 2002-05-29 CZ CZ2003-3260A patent/CZ304366B6/cs not_active IP Right Cessation
- 2002-05-29 HR HR20030943A patent/HRP20030943B1/xx not_active IP Right Cessation
- 2002-05-29 WO PCT/IB2002/001905 patent/WO2002096909A1/en not_active Ceased
- 2002-05-29 NZ NZ540332A patent/NZ540332A/en not_active IP Right Cessation
- 2002-05-29 SK SK50033-2011A patent/SK288192B6/sk active Protection Beyond IP Right Term
- 2002-05-29 CN CNA028108175A patent/CN1729192A/zh active Pending
- 2002-05-29 EP EP02733058A patent/EP1392694A1/en not_active Withdrawn
- 2002-05-29 PL PL02367945A patent/PL367945A1/xx unknown
- 2002-05-29 EA EA200600575A patent/EA012666B1/ru active Protection Beyond IP Right Term
- 2002-05-29 SK SK1465-2003A patent/SK288199B6/sk unknown
- 2002-05-30 AR ARP020102017A patent/AR037321A1/es not_active Application Discontinuation
- 2002-05-30 MY MYPI20021988A patent/MY129649A/en unknown
- 2002-05-30 PA PA20028546301A patent/PA8546301A1/es unknown
- 2002-05-30 GT GT200200100AK patent/GT200200100AA/es unknown
- 2002-05-30 GT GT200200100A patent/GT200200100A/es unknown
- 2002-05-30 UY UY27317A patent/UY27317A1/es not_active Application Discontinuation
- 2002-05-31 AP APAP/P/2002/002550A patent/AP1859A/en active
2003
- 2003-10-13 IS IS6993A patent/IS3023B/is unknown
- 2003-10-13 CU CU20030229A patent/CU23337B7/es not_active IP Right Cessation
- 2003-10-14 ZA ZA200307982A patent/ZA200307982B/en unknown
- 2003-11-21 MA MA27410A patent/MA27029A1/fr unknown
- 2003-11-24 NO NO20035201A patent/NO328578B1/no not_active IP Right Cessation
- 2003-11-26 EC EC2003004865A patent/ECSP034865A/es unknown
- 2003-11-27 BG BG108389A patent/BG66489B1/bg unknown
2004
- 2004-05-07 AR ARP040101561A patent/AR045680A2/es unknown
- 2004-06-16 US US10/869,101 patent/US7432370B2/en not_active Expired - Lifetime
2008
- 2008-03-14 CL CL200800762A patent/CL2008000762A1/es unknown
- 2008-07-16 AU AU2008203170A patent/AU2008203170B2/en active Active
- 2008-07-24 CR CR10177A patent/CR10177A/es unknown
2009
- 2009-10-13 NO NO20093135A patent/NO20093135L/no not_active Application Discontinuation
2012
- 2012-11-09 CY CY20121101069T patent/CY1113322T1/el unknown
2017
- 2017-08-02 NL NL300887C patent/NL300887I2/nl unknown
- 2017-08-08 LT LTPA2017025C patent/LTC1666481I2/lt unknown
- 2017-08-09 LU LU00031C patent/LUC00031I2/fr unknown
- 2017-08-17 BE BE2017C032C patent/BE2017C032I2/fr unknown
- 2017-09-01 CY CY2017028C patent/CY2017028I1/el unknown
- 2017-09-04 FR FR17C1031C patent/FR17C1031I2/fr active Active
- 2017-09-08 NO NO2017047C patent/NO2017047I1/no unknown
2019
- 2019-02-19 HU HUS1900008C patent/HUS1900008I1/hu unknown

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4814477A (en) *	1984-10-24	1989-03-21	Oce-Nederland B.V.	Dioxaphosphorinanes, their preparation and use for resolving optically active compounds
JPH07330732A (ja) *	1994-06-10	1995-12-19	Kyorin Pharmaceut Co Ltd	光学活性な３−アミノ−１−ベンジルピペリジン誘導体
WO1999065908A1 (en) *	1998-06-19	1999-12-23	Pfizer Products Inc.	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO1999065909A1 (en) *	1998-06-19	1999-12-23	Pfizer Products Inc.	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2001042246A2 (en) *	1999-12-10	2001-06-14	Pfizer Products Inc.	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2002000661A1 (en) *	2000-06-26	2002-01-03	Pfizer Products Inc.	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS

Also Published As

Publication number	Publication date
TWI316061B (en)	2009-10-21
HRP20030943A2 (en)	2005-08-31
PE20030561A1 (es)	2003-06-23
KR20060133117A (ko)	2006-12-22
SK288199B6 (sk)	2014-06-03
US7432370B2 (en)	2008-10-07
FR17C1031I2 (fr)	2018-11-02
NZ540332A (en)	2007-05-31
EE05332B1 (et)	2010-08-16
US20030073719A1 (en)	2003-04-17
KR20080002931A (ko)	2008-01-04
PL228155B1 (pl)	2018-02-28
MXPA03011062A (es)	2004-03-19
LTC1666481I2 (lt)	2018-06-25
DK1666481T3 (da)	2012-10-15
NO20035201L (no)	2003-11-24
EA007251B1 (ru)	2006-08-25
NO20093135L (no)	2003-11-24
EP1666481A2 (en)	2006-06-07
AP2002002550A0 (en)	2002-06-30
AR045680A2 (es)	2005-11-09
AU2002304401B2 (en)	2008-04-17
BE2017C032I2 (is)	2021-07-19
EE200300594A (et)	2004-04-15
CL2008000762A1 (es)	2008-07-04
EP1666481B9 (en)	2013-05-01
AP1859A (en)	2008-07-02
TW200413370A (en)	2004-08-01
HUS1900008I1 (hu)	2020-02-28
CY1113322T1 (el)	2016-06-22
SI1666481T1 (sl)	2012-11-30
AU2008203170B2 (en)	2009-06-18
CY2017028I2 (el)	2018-02-14
SK14652003A3 (sk)	2004-05-04
EP1666481B1 (en)	2012-09-19
YU92303A (sh)	2006-08-17
GT200200100AA (es)	2007-07-06
HU230876B1 (hu)	2018-11-29
LUC00031I1 (is)	2017-08-10
OA12612A (en)	2006-06-09
EA012666B1 (ru)	2009-12-30
US20040229923A1 (en)	2004-11-18
RS52144B (sr)	2012-08-31
BG108389A (bg)	2005-01-31
NO20035201D0 (no)	2003-11-24
BG66489B1 (bg)	2015-05-29
CN1729192A (zh)	2006-02-01
KR100869409B1 (ko)	2008-11-21
CY2017028I1 (el)	2018-02-14
PT1666481E (pt)	2012-12-03
JP2004534047A (ja)	2004-11-11
EP1609781A1 (en)	2005-12-28
KR20040003037A (ko)	2004-01-07
IS6993A (is)	2003-10-13
FR17C1031I1 (fr)	2017-10-13
TWI310384B (en)	2009-06-01
EP1392694A1 (en)	2004-03-03
ES2393385T3 (es)	2012-12-20
SK288192B6 (sk)	2014-06-03
KR20060014459A (ko)	2006-02-15
AR037321A1 (es)	2004-11-03
NO328578B1 (no)	2010-03-22
ZA200307982B (en)	2004-10-14
CA2448281A1 (en)	2002-12-05
MY129649A (en)	2007-04-30
HUP0400152A3 (en)	2012-12-28
EP1666481A3 (en)	2006-11-29
PA8546301A1 (es)	2003-05-14
GEP20063784B (en)	2006-04-10
CR10177A (es)	2008-08-19
WO2002096909A1 (en)	2002-12-05
PL409305A1 (pl)	2014-12-22
NO2017047I1 (no)	2017-09-08
PL367945A1 (en)	2005-03-07
ATE519741T1 (de)	2011-08-15
LUC00031I2 (is)	2017-10-11
LTPA2017025I1 (lt)	2017-09-11
AU2008203170A1 (en)	2008-08-07
EP1609781B1 (en)	2011-08-10
ES2369226T3 (es)	2011-11-28
KR20080083028A (ko)	2008-09-12
IS3023B (is)	2020-08-15
GT200200100A (es)	2003-02-11
MA27029A1 (fr)	2004-12-20
UA80093C2 (uk)	2007-08-27
HUP0400152A2 (en)	2007-07-30
AU2002304401C1 (en)	2009-03-05
CA2448281C (en)	2009-05-05
US7301023B2 (en)	2007-11-27
KR100926875B1 (ko)	2009-11-16
CZ304366B6 (cs)	2014-04-02
JP4381137B2 (ja)	2009-12-09
NZ530380A (en)	2005-08-26
TNSN03128A1 (fr)	2005-12-23
EA200301193A1 (ru)	2004-04-29
IL158588A0 (en)	2004-05-12
ECSP034865A (es)	2004-01-28
CU23337B7 (es)	2009-01-20
EA200600575A1 (ru)	2006-08-25
NL300887I2 (nl)	2017-08-31
KR100868814B1 (ko)	2008-11-14
CZ20033260A3 (en)	2004-03-17
BR0209246A (pt)	2004-06-15
UY27317A1 (es)	2003-02-28

Publication	Publication Date	Title
HRP20030943B1 (hr)	2011-11-30	Optičko razdvajanje (1-benzil-4-metilpiperidin-3-il)-metilamina i njegova upotreba u dobivanju pirolo 2,3-pirimidinskih derivata kao inhibitora protein kinaze
HRP20000885B1 (hr)	2007-03-31	PIROLO[2,3-d]PIRIMIDINSKI SPOJEVI
NO903851L (no)	1991-03-06	Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter.
HRP20020175B1 (hr)	2008-07-31	N-heterociklički derivati kao inhibitori nos
AR004735A1 (es)	1999-03-10	Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
AR023659A1 (es)	2002-09-04	Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
HRP20030771B1 (hr)	2008-10-31	N-(2-ariletil)benzilamini kao antagonisti 5-ht<sub>6</sub> receptora
HRP20041008B1 (hr)	2012-10-31	Derivati triazola kao antagonisti receptora tahikinina
DK1757606T3 (da)	2009-09-07	Anvendelse af xanthinderivater som l gemidler samt fremgangsm de til deres fremstilling
HRP20030565B1 (hr)	2011-12-31	Nukleozid derivati kao inhibitori rna-ovisne rna virusne polimeraze
ES2078798T3 (es)	1995-12-16	Derivados de quinazolina.
BR9810829A (pt)	2000-07-25	Composto, processo para preparar o mesmo, composição, uso de um composto ou um sal farmaceuticamente aceitável do mesmo ou uma composição, e, processo de tratamento de uma condição
BR0308146A (pt)	2004-12-07	Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
YU88901A (sh)	2004-09-03	Derivati purina
NO931366D0 (no)	1993-04-14	1,2,4-oksadiazolylfenoksyalkylisoksazoler og deres anvendelse som antivirale midler
KR960701055A (ko)	1996-02-24	인터로이킨-1 및 종양 괴사 인자 억제 활성을 지닌 피라졸로트리아진 (pyrazol itriazines with interleukin-1 and tumour necrosis factor in-hibitory actvity)
MEP12508A (en)	2010-06-10	Derivatives of n-/phenyl(piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics
HRP20090270B1 (hr)	2015-12-04	Derivati dioksan-2-alkil karbamata, metoda njihove pripreme i primjena istih u terapeutske svrhe
ATE442847T1 (de)	2009-10-15	Benzimidazol-derivate als mek-hemmer
BR0308145A (pt)	2004-12-07	Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
NO308248B1 (no)	2000-08-21	Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat
NO974843L (no)	1997-12-15	Benzimidazolforbindelser, farmasöytiske sammensetninger som inneholder forbindelsene og deres anvendelser
DE69724098D1 (de)	2003-09-18	Chinolin- und benzimidazolderivate als bradykinin agonisten
AR041256A1 (es)	2005-05-11	Indoles sustituidos en posicion 2,4 y su uso como moduladores de 5-ht6
AR041255A1 (es)	2005-05-11	Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso.

Legal Events

Date	Code	Title	Description
2005-08-31	A1OB	Publication of a patent application
2006-01-31	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2011-11-30	B1PR	Patent granted
2019-05-31	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20190507 Year of fee payment: 18
2020-06-12	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20200506 Year of fee payment: 19
2021-06-11	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20210511 Year of fee payment: 20
2022-06-07	PB20	Patent expired after termination of 20 years	Effective date: 20220529